| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Journal of Virology, October 2007, p. 11538-11542, Vol. 81, No. 20
0022-538X/07/$08.00+0 doi:10.1128/JVI.00581-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, 300 Herston Road, Brisbane, Queensland 4029, Australia,1 School of Medicine, University of Queensland, Brisbane, Queensland, Australia,2 Department of Haematology, Prince of Wales Hospital and Centre for Vascular Research, University of New South Wales, Kensington 2052, Australia,4 The Prince Charles Hospital, Rode Road, Chermside, and Department of Medicine, University of Queensland, Brisbane, Queensland, Australia,5 Department of Nephrology, Princess Alexandra Hospital, and Department of Medicine, University of Queensland, Brisbane, Queensland, Australia3
Received 19 March 2007/ Accepted 26 July 2007
Using ex vivo antigen-specific T-cell analysis, we found that symptomatic cytomegalovirus recrudescence in transplant recipients was coincident with reduced expression of gamma interferon (IFN-
) by virus-specific CD8+ T cells and an up-regulation of CD38 expression on these T cells, although there was no significant change in the absolute number of virus-specific cells (as assessed by major histocompatibility complex-peptide multimers). In contrast, HLA class I-matched transplant patients with asymptomatic viral recrudescence showed increased expansion of antigen-specific T cells and highly stable IFN-
expression by epitope-specific T cells. These studies suggest that a strong functional T-cell response plays a crucial role in defining the clinical outcome of acute viral recrudescence.
Published ahead of print on 8 August 2007.
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|